Information Provided By:
Fly News Breaks for May 16, 2017
BVX
May 16, 2017 | 08:58 EDT
Craig-Hallum analyst Charles Haff lowered his price target on Bovie Medical to $4.50 from $7 after the company's Q1 revenue and losses were worse than he expected, primarily due to lower than expected J-Plasma sales. However, he notes that management provided annual guidance for the first time and he views their estimates as achievable. Haff keeps a Buy rating on Bovie shares.
News For BVX From the Last 2 Days
There are no results for your query BVX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.